Rhythm Pharmaceuticals Future Growth
Future criteria checks 5/6
Rhythm Pharmaceuticals is forecast to grow earnings and revenue by 60.9% and 41.8% per annum respectively. EPS is expected to grow by 61.4% per annum. Return on equity is forecast to be -39.8% in 3 years.
Key information
60.9%
Earnings growth rate
61.4%
EPS growth rate
Biotechs earnings growth | 24.0% |
Revenue growth rate | 41.8% |
Future return on equity | -39.8% |
Analyst coverage | Good |
Last updated | 26 Apr 2024 |
Recent future growth updates
Recent updates
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22
Mar 03Rhythm Pharmaceuticals: Action Too Specific
Feb 23Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price
Jan 08We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing
Jun 17Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 05Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued
Dec 15We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Rhythm Pharmaceuticals: Revisiting The Investment Thesis
Oct 10Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours
Sep 14Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS
Sep 06Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts
Aug 08Rhythm Pharmaceuticals Q2 2022 Earnings Preview
Aug 01Rhythm Pharma gains as NICE recommends obesity drug
Jul 18Is Rhythm Pharmaceuticals (NASDAQ:RYTM) In A Good Position To Deliver On Growth Plans?
Jun 04Rhythm Pharmaceuticals: PDUFA Ahead, But Commercialization Concerns Remain
Jan 15Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 360 | 8 | -137 | 165 | 7 |
12/31/2025 | 210 | -133 | -201 | -58 | 8 |
12/31/2024 | 132 | -280 | -292 | -335 | 9 |
12/31/2023 | 77 | -185 | -142 | -136 | N/A |
9/30/2023 | 62 | -186 | -146 | -141 | N/A |
6/30/2023 | 44 | -182 | -164 | -159 | N/A |
3/31/2023 | 34 | -181 | -161 | -156 | N/A |
12/31/2022 | 24 | -181 | -174 | -173 | N/A |
9/30/2022 | 17 | -181 | -173 | -180 | N/A |
6/30/2022 | 13 | -176 | -166 | -173 | N/A |
3/31/2022 | 5 | -166 | -160 | -166 | N/A |
12/31/2021 | 3 | -70 | -139 | -146 | N/A |
9/30/2021 | 1 | -62 | -135 | -135 | N/A |
6/30/2021 | 0 | -60 | -122 | -122 | N/A |
3/31/2021 | 0 | -56 | -120 | -119 | N/A |
12/31/2020 | N/A | -134 | -122 | -122 | N/A |
9/30/2020 | N/A | -132 | -125 | -125 | N/A |
6/30/2020 | N/A | -134 | -132 | -132 | N/A |
3/31/2020 | N/A | -146 | -130 | -127 | N/A |
12/31/2019 | N/A | -141 | -126 | -123 | N/A |
9/30/2019 | N/A | -133 | -115 | -112 | N/A |
6/30/2019 | N/A | -115 | -99 | -95 | N/A |
3/31/2019 | N/A | -87 | -83 | -82 | N/A |
12/31/2018 | N/A | -74 | -63 | -62 | N/A |
9/30/2018 | N/A | -59 | -49 | -49 | N/A |
6/30/2018 | N/A | -53 | -41 | -40 | N/A |
3/31/2018 | N/A | -47 | -34 | -34 | N/A |
12/31/2017 | N/A | -38 | -30 | -29 | N/A |
9/30/2017 | N/A | -36 | N/A | -28 | N/A |
6/30/2017 | N/A | -32 | N/A | -24 | N/A |
3/31/2017 | N/A | -30 | N/A | -24 | N/A |
12/31/2016 | N/A | -29 | N/A | -23 | N/A |
9/30/2016 | N/A | -27 | N/A | -21 | N/A |
6/30/2016 | N/A | -23 | N/A | -18 | N/A |
3/31/2016 | N/A | -17 | N/A | -13 | N/A |
12/31/2015 | N/A | -12 | N/A | -7 | N/A |
9/30/2015 | N/A | -6 | N/A | -4 | N/A |
6/30/2015 | N/A | -3 | N/A | -4 | N/A |
3/31/2015 | N/A | -5 | N/A | -6 | N/A |
12/31/2014 | N/A | -6 | N/A | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RYTM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Earnings vs Market: RYTM is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: RYTM is expected to become profitable in the next 3 years.
Revenue vs Market: RYTM's revenue (41.8% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: RYTM's revenue (41.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RYTM is forecast to be unprofitable in 3 years.